Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Canagliflozin

Severe diabetic ketoacidosis and off label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Griffin B, et al. Severe Metabolic Acidosis as a Complication of an Oral SGLT-2 Inhibitor. Journal of the American Society of Nephrology 27: 378A, Nov 2016 [abstract] Griffin B, et al. Severe Metabolic Acidosis as a Complication of an Oral SGLT-2 Inhibitor. Journal of the American Society of Nephrology 27: 378A, Nov 2016 [abstract]
Metadaten
Titel
Canagliflozin
Severe diabetic ketoacidosis and off label use: case report
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-39239-5

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Cyclophosphamide

Case report

Amphotericin-B

Case report

Brodalumab

Case report

Pembrolizumab